Palomino Laboratories (PALX) EBITDA (2023 - 2025)
Palomino Laboratories (PALX) posted EBITDA of -$1.6 million for Q3 2025, down 4414.8% sequentially from -$35548.0 in Q2 2025, and down 129958.51% YoY from N/an in Q3 2024.
Palomino Laboratories (PALX) EBITDA (2023 - 2025) Analysis & Trends
Palomino Laboratories has reported EBITDA for 3 years, with the latest figure at -$1.6 million in Q3 2025.
- Quarterly EBITDA fell 129958.51% year-over-year to -$1.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$1.8 million (down 1436.54% YoY) and the FY2024 annual result came in at -$140080.0, down 66.89% from the prior year.
- EBITDA eased to -$1.6 million in Q3 2025 per PALX's latest filing, from -$35548.0 in the prior quarter.
- Over five years, EBITDA peaked at -$1234.0 in Q3 2024 and troughed at -$1.6 million in Q3 2025.
- A 3-year average of -$217336.2 and a median of -$35548.0 in 2025 frame the typical range for EBITDA.
- The sharpest annual moves came in 2024 and 2025: EBITDA jumped 97.12% in 2024, then plunged 129958.51% in 2025.
- Over 3 years, EBITDA stood at -$32574.0 in 2023, then sank by 323.53% to -$137962.0 in 2024, then plunged by 1063.31% to -$1.6 million in 2025.
- According to Business Quant data, EBITDA over the past three periods registered -$1.6 million, -$35548.0, and -$17828.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.60 Mn |
| Jun 30, 2025 | -35,548.00 |
| Mar 31, 2025 | -17,828.00 |
| Dec 31, 2024 | -137,962.00 |
| Sep 30, 2024 | -1,234.00 |
| Jun 30, 2024 | -31,791.00 |
| Mar 31, 2024 | -51,304.00 |
| Dec 31, 2023 | -32,574.00 |
| Sep 30, 2023 | -42,863.00 |